Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052773 | 0.89 | CHRM4 (0.43) | HRH3PDE4BCNR2ACACBPIK3CA | |
| SCHEMBL720225 | 0.81 | GPR119 (0.44) | GPR119PTGS2ACACB | |
| SCHEMBL720913 | 0.78 | KMT2A (0.47) | RIPK2MAPK1ALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL720914 | 0.78 | KMT2A (0.47) | RIPK2MAPK1ALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL718622 | 0.77 | HRH3 (0.41) | RIPK2MAPK1ALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL717665 | 0.71 | KMT2A (0.43) | GPR119MAPK1ACACB | |
| SCHEMBL718769 | 0.70 | CTSK (0.37) | GPR119ALDH1A1CNR2PTGS2 | |
| SCHEMBL719665 | 0.69 | NPC1 (0.52) | PTGS2 | |
| SCHEMBL722541 | 0.68 | GPR119 (0.48) | GPR119 | |
| SCHEMBL719749 | 0.67 | KMT2A (0.51) | GPR119ALDH1A1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | GPR119 1/4885RIPK2 2601/4885MAPK1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.